BBNX Beta Bionics, Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
BBNX Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Medical Devices
Current Price
Live
$15.96
Analyst Target
$31.8
+99.2%
Upside
52W High
$32.71
52W Low
$8.89
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$702.63M
P/E
N/A
ROE
-47.5%
Profit margin
-87.9%
Debt/Equity
0.03
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
78%
Analysis Accuracy
BBNX exhibits a critically weak Piotroski F-Score of 1/9, indicating severe financial distress, and lacks an Altman Z-Score, preventing a full solvency assessment. Despite strong revenue growth of 63.1% YoY and a robust gross margin of 54.51%, the company is deeply unprofitable with negative operating and net margins, deteriorating earnings, and a negative Forward P/E of -9.72. Insider selling worth $1.32M over the past six months and a bearish technical trend of 0/100 further signal lack of confidence. While analysts maintain a strong_buy consensus with a $31.80 target price, the current fundamentals and cash flow opacity suggest substantial risk.
Key Strengths
Exceptional year-over-year revenue growth of 63.10%, significantly above sector average of 38.87%
High gross margin of 54.51%, indicating strong pricing power or cost control in core operations
Exceptionally strong liquidity position with a current ratio of 10.64 and quick ratio of 9.57
Very low debt/equity ratio of 0.03, suggesting minimal leverage risk
Analyst consensus is strong_buy with a high target price of $31.80, implying 99% upside
Key Risks
Critically low Piotroski F-Score of 1/9, signaling severe financial weakness and high risk of continued underperformance
Deeply negative profitability: -87.89% profit margin and -47.52% ROE indicate ongoing losses and poor capital efficiency
Negative Forward P/E of -9.72 reflects unprofitability and uncertainty in future earnings trajectory
Insiders have sold $1.32M in shares with zero buys in the last 6 months, signaling bearish sentiment from management
Extreme volatility and poor price performance: -48.7% in the last month and -32.5% over the past year despite recent 6M rebound
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
25
Weak
20
65
25
15
0
AI Verdict
High-risk speculative position with unproven profitability and conflicting signals between growth and financial health
Key drivers: Piotroski F-Score of 1/9, Negative earnings and margins, Strong revenue growth, Insider selling, Analyst optimism
Confidence
85%
Value
20/100
Ref P/E, PEG, Graham Number
Positives
- Low P/B of 2.38 relative to unprofitable peers
Watchpoints
- Forward P/E of -9.72 indicates unprofitability
- No Graham Number or intrinsic value available
- Price/Sales of 7.93 is high for a loss-making company
Future
65/100
Ref Growth rates
Positives
- 63.10% YoY revenue growth well above sector average
- Analyst target price implies strong future upside
Watchpoints
- Earnings growth is negative and volatile
- Q/Q EPS growth declined by 22.2%
Past
25/100
Ref Historical trends
Positives
- Some quarters beat earnings estimates (2 out of 4)
Watchpoints
- Average earnings surprise of -7.51%
- Recent quarters show large negative surprises (e.g., -123.6%)
- 1Y, 3Y, and 5Y returns all at -32.5%
Health
15/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 10.64 and quick ratio of 9.57 indicate strong short-term liquidity
- Debt/Equity of 0.03 shows minimal financial leverage
Watchpoints
- Piotroski F-Score of 1/9 indicates critical financial weakness
- No Altman Z-Score available for solvency assessment
- ROE of -47.52% and ROA of -20.08% reflect poor asset and equity efficiency
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength of 0/100
- No dividend yield or payout history
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$15.96
Analyst Target
$31.8
Upside/Downside
+99.2%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BBNX and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BBNX
Beta Bionics, Inc.
Primary
|
-32.5% | -32.5% | -32.5% | +7.5% | -48.7% | -13.7% |
|
BGM
BGM Group Ltd.
Peer
|
-90.8% | -38.2% | -66.0% | -64.4% | -12.5% | 0.0% |
|
AVR
Anteris Technologies Global Corp.
Peer
|
+15.4% | +15.4% | +8.4% | +98.8% | +19.4% | +26.4% |
|
ARVN
Arvinas, Inc.
Peer
|
-84.3% | -57.8% | +42.5% | +57.4% | -7.0% | -10.4% |
|
AMN
AMN Healthcare Services, Inc.
Peer
|
-72.8% | -78.8% | -26.3% | +3.5% | +28.0% | +7.7% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-9.72
PEG Ratio
N/A
P/B Ratio
2.38
P/S Ratio
7.93
EV/Revenue
5.44
EV/EBITDA
-7.15
Market Cap
$702.63M
Profitability
Profit margins and return metrics
Profit Margin
-87.89%
Operating Margin
-62.54%
Gross Margin
54.51%
ROE
-47.52%
ROA
-20.08%
Growth
Revenue and earnings growth rates
Revenue Growth
+63.1%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.03
Low debt
Current Ratio
10.64
Strong
Quick Ratio
9.57
Excellent
Cash/Share
$5.2
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-17
$N/A
2025-10-28
$-0.33
+19.8% surprise
2025-07-29
$-0.27
+41.4% surprise
2025-05-06
$-0.93
-83.8% surprise
Healthcare Sector Comparison
Comparing BBNX against 147 companies in the Healthcare sector
(10 bullish, 55 neutral, 82 bearish)
Return on Equity (ROE)
-47.52%
This Stock
vs
-52.77%
Sector Avg
-10.0%
(Below Avg)
Profit Margin
-87.89%
This Stock
vs
-20.78%
Sector Avg
+323.0%
(Superior)
Debt to Equity
0.03
This Stock
vs
6.16
Sector Avg
-99.6%
(Less Debt)
Revenue Growth
63.1%
This Stock
vs
137.39%
Sector Avg
-54.1%
(Slower)
Current Ratio
10.64
This Stock
vs
3.36
Sector Avg
+216.6%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BBNX
Beta Bionics, Inc.
|
BEARISH | $702.63M | - | -47.5% | -87.9% | $15.96 | |
|
BGM
BGM Group Ltd.
|
BEARISH | $746.32M | - | -16.5% | -26.3% | $3.72 | |
|
AVR
Anteris Technologies Global Corp.
|
BEARISH | $627.4M | - | -2698.5% | -% | $6.46 | |
|
ARVN
Arvinas, Inc.
|
BEARISH | $782.25M | - | -16.2% | -30.8% | $12.18 | |
|
AMN
AMN Healthcare Services, Inc.
|
BEARISH | $787.1M | - | -35.9% | -10.1% | $20.49 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-13 | MICHEL GERARD J | Director | Stock Award | 3,997 | - |
| 2026-01-13 | CARNEY SEAN D | Director | Stock Award | 3,997 | - |
| 2026-01-13 | DEAREN DANNY L | Director | Stock Award | 3,997 | - |
| 2026-01-13 | PALASIS MARIA | Director | Stock Award | 3,997 | - |
| 2026-01-13 | LEZACK ADAM | Director | Stock Award | 3,997 | - |
| 2026-01-13 | JONES CHRISTY | Director | Stock Award | 3,997 | - |
| 2026-01-06 | MENSINGER MIKE | Officer | Sale | 2,200 | $66,221 |
| 2026-01-02 | FEIDER STEPHEN | Chief Financial Officer | Option Exercise | 20,000 | $102,000 |
| 2026-01-02 | FEIDER STEPHEN | Chief Financial Officer | Sale | 20,000 | $590,680 |
| 2026-01-02 | MENSINGER MIKE | Officer | Sale | 7,800 | $230,950 |
| 2025-12-02 | SAINT SEAN | Chief Executive Officer | Sale | 3,278 | $96,163 |
| 2025-12-02 | FEIDER STEPHEN | Chief Financial Officer | Sale | 1,427 | $41,862 |
| 2025-12-02 | MENSINGER MIKE | Officer | Sale | 1,063 | $31,184 |
| 2025-12-01 | PALASIS MARIA | Director | Sale | 1,406 | $41,552 |
| 2025-12-01 | LEZACK ADAM | Director | Sale | 1,406 | $41,543 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
10 analysts
Lake Street
2026-01-09
Buy
Buy
B of A Securities
2026-01-05
Buy
Buy
Truist Securities
2025-12-18
Buy
Buy
Goldman Sachs
2025-10-29
Buy
Buy
Stifel
2025-10-29
Buy
Buy
Truist Securities
2025-10-29
Buy
Buy
Piper Sandler
2025-10-29
Overweight
Overweight
Goldman Sachs
2025-10-01
Neutral
Buy
Truist Securities
2025-09-22
Buy
Buy
Truist Securities
2025-07-30
Buy
Buy
Past News Coverage
Recent headlines mentioning BBNX from our newsroom.
Newest → oldest
No matching news yet.